Jay Olson

As the day of reckoning for Biogen Inc.'s (NASDAQ: BIIB) controversial Alzheimer's product candidate aducanumab draws close, an analyst at Oppenheimer looked at the implications of the binary event for the company. The Biogen Analyst: Analyst Jay Olson has an Outperform rating on Biogen...

Biogen Inc (NASDAQ: BIIB) shares shed close to 10% Wednesday following the revelation that the BLA filing for the company's Alzheimer's investigational drug aducanumab will be delayed. The Biogen Analysts Barclays analyst Carter Gould maintained an Overweight rating on Biogen...

Axovant Sciences Ltd (NASDAQ: AXON) announced Wednesday that it licensed global rights to Oxford BioMedica’s investigational gene therapy for Parkinson’s Disease. As some experts see it, the drug could be a game changer. The Rating Oppenheimer analysts Jay Olson and Silvan Tuerkcan...

The Medicines Company (NASDAQ: MDCO) announced Wednesday an agreement to sell its infectious disease business unit to Melinta Therapeutics, Inc. (NASDAQ: MLNT) for $270 million upfront.  As part of the deal, Medicines Company would receive royalty payments of 5-25 percent on worldwide net...

Incyte Corporation (NASDAQ: INCY) traded down 5.5 percent Wednesday despite posting 6-percent revenue and 143-percent earnings per share beat Tuesday. But analysts were more receptive to the quarterly report. BMO Capital raised its price target to $166, Barclays reiterated positive outlook and...

Axovant Sciences Ltd (NASDAQ: AXON) suffered a setback in its phase 3 trial called MINDSET in which its exploratory drug called intepirdine failed to improve the quality of life in people suffering from Alzheimer's. The drug isn't intended to be a cure for the disease but the company expected the...

Even after Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares soared nearly 50 percent following news of betrixaban receiving FDA approval (reported on Benzinga Pro), Oppenheimer analyst Jay Olson sees further upside. Olson maintains an Outperform rating on Portola with a $66 price target. A Closer...

Following the FDA issuing a complete response letter, or CRL, in response to TherapeuticsMD Inc (NYSE: TXMD)'s NDA for TX-004HR, Oppenheimer downgraded the shares of the company. TX-004HR, or Yuvvexy, is the company's applicator-free vaginal estradiol soft-gel drug candidate for the treatment...

TherapeuticsMD Inc (NYSE: TXMD) has waned as much as 40 percent since April 7, when the company received an FDA letter noting deficiencies in the new drug application for vulvovaginal atrophy treatment, Yuvvexy (TX-004HR). The regulatory agency said the deficiencies preclude talk of the drugs...